792 results about "Serine" patented technology

The invention discloses a high-performance carbonyl reductase mutant and application thereof in synthesis of a series of chiral alcohols. The high-performance carbonyl reductase mutant is obtained by performing the following mutations on an amino acid sequence as shown in SEQ ID NO.2: the 69th alanine mutates into any one of lysine, leucine, aspartic acid or asparagine, and the 69th alanine mutates into any one of lysine, leucine, aspartic acid or asparagine; and / or the 100th glycine is mutated into any one of glutamic acid, serine, lysine or asparagine. Compared with a wild type enzyme, the thermal stability and the catalytic activity of the obtained mutant are remarkably improved, particularly, single point mutants Mut-A69N, Mut-G100E and Mut-G100N and a combined mutant Mut-A69N-G100N show excellent relative enzyme activity, thermal stability and substrate tolerance. The mutant has high catalytic activity and stability to various chiral alcohols, and the contradiction that the traditional carbonyl reductase is easy to inactivate at high temperature and the catalytic efficiency is difficult to achieve at the same time is solved. The invention provides an efficient and stable enzyme catalysis tool for green biological preparation of chiral drug intermediates.

The invention discloses a cyclic nonapeptide with repairing and anti-oxidation effects and application of the cyclic nonapeptide, the amino acid sequence of the cyclic nonapeptide is cyclic (arginine-glycine-aspartic acid-serine-arginine-lysine-valine-lysine-serine), the prepared cyclic nonapeptide has the repairing and anti-oxidation effects, and the cyclic nonapeptide has the repairing and anti-oxidation effects. The composition can be applied to preparation of cosmetics with repairing and / or anti-oxidation effects.

The invention discloses keratinase Phyto-Keratinase and application of the keratinase Phyto-Keratinase. The keratinase Phyto-Keratinase comprises the following components: (1) protease which is coded by a nucleotide sequence as shown in SEQ ID NO.1; and / or (2) protease which is derived from bacillus subtilis, is coded by a nucleic acid sequence with more than 98% of identity with the SEQ ID NO.1 nucleotide sequence and has the characteristic of hydrolyzing keratin. According to the plant keratinase Phyto-Keratinase disclosed by the invention, the Phyto-Keratinase (plant keratinase) produced by utilizing microbial fermentation is a serine proteolytic enzyme, is also a biocompatible cutinase, and is obtained by fermenting saccharomyces cerevisiae. Phyto-Keratinase provides a nitrogen source for the growth of plants (beans), and contains various amino acids (functional peptides) and special proteolytic enzymes derived from the plants at the same time. The Phyto-keratinase can provide the effects of resisting inflammation, removing cutin and providing nutrition for skin regeneration at the same time, can relieve various inflammations by inhibiting PAR-2 receptors, and has potential value in the fields of cosmetics, beauty medicine and environment.

The invention relates to the technical field of carotenoid cleavage dioxygenase, and discloses a carotenoid cleavage dioxygenase mutant and application thereof. In order to improve the efficiency of converting carotenoid in tobacco into aroma molecule beta-ionone, specific mutation of characteristic sites is carried out on carotenoid cleavage dioxygenase (PhCCD1) from petunia, that is, serine (S) at the 428 site of the carotenoid cleavage dioxygenase is mutated into cysteine (C) or tyrosine (Y) to obtain a mutant S428C or S428Y, and the mutant S428C or S428Y is converted into beta-ionone. The yield of the beta-ionone converted from the carotenoid is greatly improved. Experiments prove that the yields of beta-ionone of S428C and S428Y respectively reach 54.2 mg / L and 50.6 mg / L, which are respectively increased by 69.7% and 58.5% compared with those of a wild strain WT.

The invention belongs to the technical field of biology, and particularly relates to application of serine in relieving heat stress of pleurotus ostreatus and a method. Under the heat stress condition, exogenous serine supply promotes pleurotus ostreatus hypha to recover growth, and the activity of antioxidant enzyme, the yield of sporocarp and the yield of nutrient substances are improved; when the activity of the PHGDH enzyme is inhibited, the serine synthesis is reduced; the hypha growth can be promoted by overexpressing the phgdh, and the enzymatic activity of the PHGDH can be improved; when acetyltransferases HAT, NAT1, NAT2 and NAT3 act on a K394 site of the PHGDH, the enzyme activity of the PHGDH can be improved, endogenous serine metabolism is activated to respond to heat stress, it is indicated that PHGDH-mediated serine metabolism plays an important role in corresponding heat stress of the pleurotus ostreatus, and the invention discloses a mechanism for improving heat resistance of the pleurotus ostreatus through the PHGDH-mediated serine metabolism. And a foundation can be laid for breeding high-temperature-resistant pleurotus ostreatus dominant strains.

The invention relates to the technical field of related drugs for nerve injury caused by heavy metal pollution, in particular to application of a compound for inhibiting phosphorylation of ARMC10 in preparation of drugs for antagonizing tin-induced nervous system injury. Exposure of trimethyltin chloride induces nerve cell mitochondrial dysfunction, and the key mechanism is ARMC10 serine 43 site abnormal phosphorylation. Phosphorylated protein causes excessive mitochondrial fission, membrane potential collapse and energy metabolism disorder, resulting in neuron damage. Based on the target spot, a compound for antagonizing tin-induced nervous system injury is obtained through screening, protein phosphorylation can be specifically inhibited, mitochondrial dynamic unbalance and dysfunction induced by trimethyltin chloride are effectively reversed, and neurotoxicity is relieved. According to the technical scheme, the technical problem that in the prior art, no medicine for effectively antagonizing tin-induced nervous system injury exists can be solved, and the compound has the application potential for treating the nervous system injury and cognitive impairment caused by tin exposure.

The invention relates to the technical field of functional food and biological medicine, in particular to a modified pseudo-ginseng exosome and an intestinal conditioning gel composition and application thereof. According to the gel beverage, an exosome derived from panax notoginseng callus cultured in a laboratory is used as a core active component, is modified through phosphatidylserine-aminated pectin-genipin and is embedded into a hydrogel matrix composed of carboxymethyl chitosan and sodium alginate, so that the exosome is protected from being degraded in the stomach, and the activity of the exosome in the stomach is improved. The exosome can be effectively released under the intestinal pH and flora environment, so that the targeted delivery of the intestinal tract is realized, and the preparation method is suitable for improving the intestinal inflammation and maintaining the intestinal health. The invention can effectively solve the technical problems of uncontrollable raw material quality and safety, low oral delivery stability and active ingredient availability and poor medication compliance of the existing plant exosome.

The invention discloses a yak bone collagen peptide for improving osteoporosis and preparation and application thereof, and relates to the field of biological medicine, the yak bone collagen peptide comprises collagen peptide with the molecular weight of 500-2000 Daltons, contains a glycine-proline-hydroxyproline tripeptide core structure, can promote osteoblast differentiation and inhibit osteoclast activity, and can be used for treating osteoporosis. The amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine, and the amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine; and the amino acid is glycine, proline, hydroxyproline, serine, leucine and alanine. The yak bone collagen peptide has a unique glycine-proline-hydroxyproline tripeptide structure, the molecular weight is controlled within the range of 500-2000 Daltons, the structure can promote osteoblast differentiation and inhibit osteoclast activity at the same time, and the problem that a traditional osteoporosis treatment medicine is single in function is solved.

Among other things, provided herein are systems that replace the natural random integration activity of a retrovirus with site-specific integration machinery. This approach allows for a more precise targeting of a gene of interest into a human genome, e.g., for therapeutic purposes. The system may include integration-deficient retrovirus (e.g., lentivirus) (IDLV), in which the natural integration activity has been reduced (e.g., by mutation to the viral integrase polypeptide). Instead, the system may comprise a site-specific recombinase (e.g., a serine recombinase, e.g., a serine integrase) capable of directing insertion of a template DNA, or portion thereof, into a desired site in the human genome.

The invention discloses an amino acid composition for treating alopecia and application of the amino acid composition in preparation of a medicine for treating alopecia, and belongs to the field of medicine configuration products, the amino acid composition is composed of a targeting core intervention component and an auxiliary strengthening synergistic component, the targeting core intervention component is prepared from 30-50 parts of arginine, 50-155 parts of lysine and 50-120 parts of glutamic acid, and the auxiliary strengthening synergistic component is prepared from an auxiliary strengthening synergistic component and an auxiliary strengthening synergistic component. 10 to 40 parts of cysteine and 20 to 60 parts of leucine; the auxiliary strengthening synergistic component is prepared from 15 to 45 parts of tyrosine, 15 to 40 parts of glycine, 10 to 40 parts of glutamine, 20 to 35 parts of serine, 5 to 25 parts of alanine, 2 to 20 parts of aspartic acid and 15 to 35 parts of phenylalanine; the composition can be used as an active ingredient to be prepared into different dosage forms such as a pigmentum, a spray, an ointment and a liniment, is applied to prevention of alopecia and promotion of hair growth, and has a remarkable treatment effect.

According to the scheme, the invention provides the recombinant macrolide enzyme as well as the preparation method and the application thereof, the amino acid sequence of the recombinant macrolide enzyme is as shown in SEQ ID NO.1, and the recombinant macrolide enzyme is derived from an EreC esterase family of enterobacter hormaechei and is obtained through site-specific mutagenesis; the mutation sites are as follows: glutamic acid at the 44th site is mutated into asparagine, tyrosine at the 55th site is mutated into proline, proline at the 76th site is mutated into arginine, phenylalanine at the 153rd site is mutated into alanine, and serine at the 219th site is mutated into glutamic acid. The method is expected to remove macrolide antibiotic pollution, and has good economic benefits and practical values.

The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises, preferably consists of, at least one empty liposome selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; (b) an empty liposome consisting of sphingomyelin; and (c) an empty liposome comprising, preferably consisting of, phosphatidylcholine and sphingomyelin; and at least one empty liposome independently of each other selected from an empty liposome comprising, preferably consisting of, lipids or phospholipids selected from cholesterol, sphingomyelins, ceramides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, diacylglycerols, and phosphatidic acids containing one or two or more saturated or unsaturated fatty acids longer than 4 carbon atoms and up to 28 carbon atoms; for use in a method for preventing or reducing biofilm formation or for eradicating or reducing existing biofilm.

The invention discloses an engineered glycosyl transferase and application thereof in efficient preparation of triterpenoid saponin. The engineered glycosyl transferase is obtained by mutating serine at the 15th site of UGT74AC1 enzyme into alanine, mutating histidine at the 47th site into aspartic acid, mutating leucine at the 48th site into valine, mutating alanine at the 180th site into serine, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid, mutating histidine at the 180th site into aspartic acid The mutant is obtained by mutating serine at the 332 site into proline, phenylalanine at the 367 site into tryptophan and lysine at the 420 site into arginine. According to the invention, the glycosyl transferase with high catalytic activity is obtained by modifying an enzyme engineering technology, and good application of the glycosyl transferase in synthesis of triterpenoid saponin is realized. The glycosyl transferase disclosed by the invention can also be coupled with sucrose synthase, or coupled with N-acetylhexosamine kinase and N-acetylglucosamine-1-uridine phosphate transferase, and acetylglucosamine is used as a glycosyl donor, so that cascade production of triterpenoid saponin with lower cost and higher efficiency is realized.

The invention relates to the technical field of technical gene detection, in particular to a recombinase and recognition site screening method and system based on structure classification prediction.The method comprises the steps that to-be-matched recombinase is obtained for structure resolution prediction.The functional domain of the to-be-matched recombinase is obtained; searching in a first database according to the functional domain, searching candidate recombinase of which the similarity meets a preset condition, and screening to obtain optimal recombinase; determining an interaction region of the current large serine recombinase and the target DNA sequence from a second database, and sequentially obtaining interaction amino acid sequences corresponding to the preferable recombinase; and matching with the amino acid characteristic sequence of the current large serine recombinase in the second database to obtain the target large serine recombinase with the highest similarity in the preferred recombinase and the corresponding recognition site sequence. According to the method, the structure of the large protein is subjected to structure comparison mining and splitting, and recognition site prediction is performed on interaction region amino acid characteristics, so that the research and development period is shortened, and the research and development cost is saved.

The present disclosure provides a recombinant Escherichia coli strain modified by metabolic engineering means and a method for producing L-homoserine by using the same. The strain, designated as Escherichia coli having a strain number of 13-XA, is deposited in China General Microbiological Culture Collection Center (CGMCC) with an accession number of CGMCC No. 25099, dated Jun. 16, 2022. With respect to the chromosome DNA thereof, one or more genes associated with fatty acid metabolism are knocked out or attenuated, and / or a promoter is replaced for enhancement; one or more genes associated with the L-homoserine metabolic pathway are knocked out or attenuated, and / or one or more genes associated with the L-homoserine metabolic pathway are overexpressed or enhanced, and / or one or more genes associated with the L-homoserine metabolic pathway are mutated.

The present invention relates to an isolated peptide comprising the amino acid sequence of Formula (I): (O)n-K-(O)m-Z; wherein K is lysine optionally modified with a self-immolative moiety Z is tryptophan or is absent; O is GHGX1Y (SEQ ID NO: 1); G is glycine, H is histidine, Y is tyrosine; each X1 is independently selected from alanine, glycine, serine, asparagine, histidine (H), arginine (R), aspartic acid, tyrosine, and proline; n is 0 – 5; m is 0 – 5; n+m is 3, 4, 5, 6, 7 or 8, and optionally, wherein not all of the X1 residues are proline (P). Such peptide is a coacervate forming peptide. The present invention also relates to methods of preparing coacervate compositions comprising the isolated peptide, optionally also comprising one or more biomacromolecules (payloads). The present invention further relates to the coacervate compositions per se, and their uses, e.g. in methods of treatment or diagnosis.

The invention discloses a preparation method of semeglutide, which comprises the following steps: respectively using 8-bit and 12-bit single pseudo-proline serine in a combined manner, using 1-2-bit, 3-4-bit, 5-6-bit and 29-30-bit dipeptide fragments in a combined manner, using 27-29-bit and 14-16-bit 2, 4-dimethoxy benzyl modified glycine tripeptide fragments in a combined manner, and further comprising a 20-bit lysine fragment with a side chain group, the method is used for synthesizing semeglutide resin, and the semeglutide resin is cracked and purified to obtain the semeglutide. The preparation method combining the fragments is beneficial to completing solid phase coupling of the semeglutide, greatly improves the substitution value of the semeglutide peptide resin and the purity and yield of a crude product, remarkably reduces the purification difficulty of the crude product, finally reduces the synthesis cost, and is beneficial to industrial mass production.

The invention discloses a serine hydroxymethyltransferase mutant and an application thereof in production of L-serin.The serine hydroxymethyltransferase mutant with the specific enzyme activity remarkably improved is obtained by conducting saturated mutation on serine hydroxymethyltransferase from escherichia coli and conducting screening, and the serine hydroxymethyltransferase mutant is applied to synthesis of L-serine. The serine hydroxymethyltransferase disclosed by the invention can be used for effectively improving the efficiency of catalyzing glycine and formaldehyde to synthesize L-serine by using the serine hydroxymethyltransferase, reducing the enzyme dosage, remarkably reducing the production cost and reducing the separation difficulty of downstream products.

The invention discloses application of an exogenous regulating substance in relieving corn drought stress, and belongs to the technical field of biology. It is verified that external application of serine, pantothenic acid or raffinose can promote root morphology establishment of corn under drought stress, enhance antioxidant enzyme activity of corn roots, reduce MDA accumulation and increase soluble protein content, 0.6 mM of serine, 0.9 mM of pantothenic acid and 1.0 mM of raffinose can effectively relieve stress of the drought environment on corn, and the corn drought resistance can be effectively improved. The water retention capacity of corn is improved, the antioxidant enzyme activity of corn roots is enhanced, the content of osmotic regulation substances is regulated and controlled, damage of drought stress to corn cells is reduced, and meanwhile growth of corn plants and establishment of root morphology are promoted. The invention provides a new strategy for drought-resistant cultivation of corn.

The invention discloses bacillus subtilis Bs1 as well as an antagonistic substance and application thereof. According to the invention, Bs1 with antagonism on colletotrichum gloeosporioides is separated and screened for the first time, an antagonistic substance is clear as Bs1 serine-producing protease Vpr, a Bs1 bacteriostasis mechanism and biological control potential excavation are analyzed in a multi-omics manner, a peripheral colonization rule of Bs1-Rif is clear, and an indoor control strategy of the strain Bs1 on cunninghamia lanceolata anthracnose is optimized. When the strain Bs1 is applied on the day when pathogenic bacteria are inoculated, a certain prevention and treatment effect is achieved, and it is indicated that the strain Bs1 can rapidly occupy the ecological niche; the average antibacterial rate of the strain Bs1 can reach 66.69%. The biocontrol strain and theoretical basis are provided for prevention and control of Chinese fir diseases, the application of biological prevention and control in forestry is promoted, the interaction mechanism of biocontrol bacteria and pathogenic bacteria can be deeply understood, and the sustainable development requirement of modern forestry is met.

The invention discloses a preparation method of a nano-liposome coated NAD amino acid nutrient solution, and relates to the technical field of liposome amino acid nutrient solution preparation, the preparation method comprises the following steps: S1, preparing raw materials: S1.1, preparing NAD amino acid; s1.2, lecithin: using pure natural lecithin from soybeans and eggs; s1.3, preparing sodium hyaluronate: adopting sodium hyaluronate with low molecular weight; s1.4, preparing an amino acid compound, wherein the amino acid compound contains a plurality of essential amino acids, including glycine, serine and lysine; according to the mask, when the NAD amino acid nutrient solution wrapped by the nano-liposome is applied to the mask, the mask can more effectively permeate into the deep layer of the skin due to the excellent stability and biological activity of the NAD amino acid nutrient solution, and sufficient nutrition and moisture are provided for the skin; meanwhile, due to the strong anti-aging effect, the mask can remarkably improve the skin texture, reduce fine wrinkles and wrinkles, and make the skin more compact, smoother and elastic.

The invention discloses a casein peptide composition containing multifunctional peptide and a preparation method of the casein peptide composition. The present invention provides a casein peptide composition containing a multifunctional peptide, characterized in that the casein peptide composition is obtained by enzymatic hydrolysis of a casein liquid, in the casein peptide composition, the relative strength of total functional peptides is 25% or more, the relative strength of casein phosphopeptides is 9% or more, and the relative strength of the casein phosphopeptides is 9% or more. The relative strength of the functional peptides except the casein phosphopeptides is above 11%, and the enzyme in the enzymolysis at least comprises serine protease.

Compositions and related methods and uses are provided comprising sotebercept and variants thereof wherein the variants undergo a peptide bond cleavage between arginine 4 and serine 5 (Arg (4)-Ser (5) of the amino acid sequence (SEQ ID NO: 2) of one or two monomeric peptide chains of sotebercept, calculated based on peptide mass fingerprinting analysis, and wherein the variants have a peptide bond cleavage between arginine 4 and serine 5 (Arg (4)-Ser (5) of one or two monomeric peptide chains of sotebercept. The variant content is less than or equal to about 10%. The invention further provides a pharmaceutical preparation containing the composition and a preparation method of the pharmaceutical preparation. In addition, the invention also provides a detection method of the variant and application of the variant in quality inspection or quality control of a product containing sotebercept.

The invention belongs to the technical field of biology, and discloses a transaminase GabT1 mutant S106I, a construction method thereof and application of the transaminase GabT1 mutant S106I in biosynthesis of 1-deoxynojirimycin. According to the invention, the 106th serine near the molecular catalytic domain of the transaminase GabT1 derived from bacillus amyloliquefaciens is mutated into isoleucine in a site-directed mutagenesis manner, so that the catalytic efficiency of the transaminase GabT1 is remarkably improved, the problem that the catalytic efficiency of the transaminase GabT1 on fructose-6-phosphoric acid is not high at present is solved, and the application of the transaminase GabT1 to the fructose-6-phosphoric acid is promoted. The yield of 1-deoxynojirimycin synthesized by the mutant GabTS106I is increased by 43.87% compared with that of a wild type. The 1-deoxynojirimycin fermentation production capability of the transaminase GabT1 mutant and the engineering strain obtained by the invention is greatly improved, and the transaminase GabT1 mutant and the engineering strain have a good industrial application prospect.

A CVB virus expression vector comprising a PIV5 W3A viral genome comprising a mutation at amino acid residue S157 or S156 of the P / V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) with phenylalanine (F) or asparagine (N), and the SH gene has a deletion of the SH open reading frame or the entire SH gene transcription unit. The CVB virus expression vector expresses a heterologous polypeptide, including SARS-CoV-2 spike (S), and / or nucleocapsid (N) and / or membrane (M) proteins, RSV fusion protein (F), or other antigens.

The present invention relates to nuclear mitotic apparatus (NuMA) protein serine 395 (S395) phosphorylation inhibitor for use in preventing and / or treating cancer in a subject. The invention also relates to a pharmaceutical composition comprising a NuMA S395 phosphorylation inhibitor. Furthermore, the invention provides a method of screening for a candidate compound for preventing and / or treating cancer, and a method of detecting a dormant cancer cell in a subject. Corresponding methods of treating and / or preventing cancer are also provided.

The invention provides a single-chain and double-protein-expressed circular RNA construct and a preparation method and application thereof, and the single-chain and double-protein-expressed circular RNA construct comprises 5'and 3 'introns used for realizing RNA self-splicing and cyclization as a first kind of introns; the 5'and 3 'homologous arms are used as pairing sites in RNA molecules; the exon 1 and the exon 2, which are connected after being spliced, can be spliced and connected together under the action of the first type of introns to form a complete and continuous open reading frame; an interval sequence for providing spatial and adjustment sequence structures; the IRES is used for starting translation; a glycine-serine linker as a flexible linker; a green fluorescent protein for gene expression monitoring; a luciferase for producing light by a catalytic chemical reaction. All the advantages of the double-IRES system for generating natural complete protein are reserved, and the core defect of low efficiency can be thoroughly overcome.

Disclosed herein are engineered LSR sequences, compositions, and uses including in genome-editing systems and therapeutic compositions. The LSRs can facilitate nucleic acid recombination at particular attachment sites, using suitable donor sequences. The disclosed LSRs may be used to site-specifically recombine or integrate nucleic acid sequences for a variety of purposes, including treatment of human diseases.

The invention relates to a phospholipase D mutant Lip-Gri / NQ, a plasmid, a recombinant bacterium and application of the phospholipase D mutant Lip-Gri / NQ and belongs to the field of enzyme engineering, the amino acid sequence of the phospholipase D mutant is shown as SEQ ID NO: 1, and the nucleotide sequence of a gene for coding the phospholipase D mutant Lip-Gri / NQ is shown as SEQ ID NO: 2. The invention also provides a recombinant plasmid and an engineering bacterium containing the gene of the recombinant plasmid phospholipase D mutant Lip-Gri / NQ, and application of the phospholipase D mutant Lip-Gri / NQ in catalyzing phospholipids to generate specific-configuration functional lipids including phosphatidylserine. According to the phospholipase D Lip-Gri disclosed by the invention, wild phospholipase D Lip-Gri from Streptomyces griseofuscus is transformed through site-directed mutagenesis, and the enzyme activity of the obtained mutant is remarkably improved and is 11 times that of the wild phospholipase D Lip-Gri.

To provide agents for promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production by finding substances having excellent activity in promoting epidermal keratinocyte growth, filaggrin mRNA expression, serine palmitoyltransferase mRNA expression, involucrin expression or ATP production.SOLUTION: An epidermal keratinocyte growth promoting agent of the invention comprises one or more effective ingredients selected from the group consisting of 2-ketoglutaric acid, 2-isopropyl malate, inosine 5'-monophosphoric acid, succinic acid, malic acid and pyruvic acid. Also, a filaggrin mRNA expression promotor, a serine palmitoyltransferase mRNA expression promotor, an involucrin expression promotor of the invention comprise, as an effective ingredient, 2-ketoglutaric acid. Further an ATP production promotor of the invention comprises 2-isopropyl malate as an effective ingredient.SELECTED DRAWING: None